• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Management System Approach for Addressing Biosafety and Biosecurity of Emerging Pathogens in a Biosafety Level-3 Core Facility.生物安全3级核心设施中应对新出现病原体生物安全和生物安保的管理体系方法
Appl Biosaf. 2021 Dec 1;26(4):210-220. doi: 10.1089/apb.2021.0007. Epub 2021 Nov 24.
2
Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility.生物安全三级实验室中 SARS-CoV-2 研究的生物风险管理。
Methods Mol Biol. 2022;2452:441-464. doi: 10.1007/978-1-0716-2111-0_24.
3
Strengthening Biorisk Management in Research Laboratories with Security-Sensitive Biological Agents Like SARS-CoV-2.利用如SARS-CoV-2等具有安全敏感性的生物制剂加强研究实验室的生物风险管控。
Methods Mol Biol. 2022;2452:395-439. doi: 10.1007/978-1-0716-2111-0_23.
4
Mobile High-Containment Biological Laboratories Deployment: Opportunities and Challenges in Expeditionary Deployments to Outbreak Response.移动高防护生物实验室的部署:疫情应对远征部署中的机遇与挑战
Appl Biosaf. 2019 Mar 1;24(1):20-29. doi: 10.1177/1535676018818563.
5
Assessment of biorisk management systems in high containment laboratories, 18 countries in Europe, 2016 and 2017.评估高防护实验室的生物风险管理系统,欧洲 18 个国家,2016 年和 2017 年。
Euro Surveill. 2020 Sep;25(36). doi: 10.2807/1560-7917.ES.2020.25.36.2000089.
6
The Biosafety Research Road Map: The Search for Evidence to Support Practices in Human and Veterinary Laboratories.生物安全研究路线图:寻找支持人类和兽医实验室实践的证据。
Appl Biosaf. 2023 Jun 1;28(2):64-71. doi: 10.1089/apb.2022.0040. Epub 2023 Jun 5.
7
Assessment of the Biosafety and Biosecurity Landscape in the Philippines and the Development of the National Biorisk Management Framework.菲律宾生物安全与生物安保状况评估及国家生物风险管理制度框架的制定
Appl Biosaf. 2021 Dec 1;26(4):232-244. doi: 10.1089/apb.20.0070. Epub 2021 Nov 24.
8
Biosafety and biosecurity capacity building: insights from implementation of the NUITM-KEMRI biosafety training model.生物安全与生物安保能力建设:NUITM-肯尼亚医学研究协会生物安全培训模式实施的见解
Trop Med Health. 2018 Aug 8;46:30. doi: 10.1186/s41182-018-0108-7. eCollection 2018.
9
Managing Biorisk Linked to Rapidly Expanding SARS-CoV-2 Research.应对与快速扩展的SARS-CoV-2研究相关的生物风险
Appl Biosaf. 2020 Sep 1;25(3):132-133. doi: 10.1177/1535676020942354.
10
A Multilingual Tool for Standardized Laboratory Biosafety and Biosecurity Assessment and Monitoring.一种用于标准化实验室生物安全和生物安保评估和监测的多语言工具。
Health Secur. 2022 Nov-Dec;20(6):488-496. doi: 10.1089/hs.2022.0030. Epub 2022 Nov 16.

引用本文的文献

1
Biosafety Management Practices Among Clinical Laboratory Professionals in Debre Berhan Town Governmental Hospitals, Ethiopia: A Cross-Sectional Study.埃塞俄比亚德布雷伯汉镇政府医院临床实验室专业人员的生物安全管理实践:一项横断面研究
Health Sci Rep. 2025 Jan 27;8(1):e70361. doi: 10.1002/hsr2.70361. eCollection 2025 Jan.
2
The Role of the Biosafety Cabinet in Preventing Infection in the Clinical Laboratory.生物安全柜在临床实验室预防感染中的作用。
Cureus. 2023 Dec 29;15(12):e51309. doi: 10.7759/cureus.51309. eCollection 2023 Dec.

本文引用的文献

1
Considerations for Laboratory Biosafety and Biosecurity During the Coronavirus Disease 2019 Pandemic: Applying the ISO 35001:2019 Standard and High-Reliability Organizations Principles.2019年冠状病毒病大流行期间实验室生物安全和生物安保的考量:应用ISO 35001:2019标准和高可靠性组织原则
Appl Biosaf. 2021 Sep 1;26(3):113-122. doi: 10.1089/apb.20.0068. Epub 2021 Sep 13.
2
The Culture of Biosafety, Biosecurity, and Responsible Conduct in the Life Sciences: A Comprehensive Literature Review.生命科学中的生物安全、生物安保与负责任行为文化:全面文献综述
Appl Biosaf. 2019 Mar 1;24(1):34-45. doi: 10.1177/1535676018778538.
3
ANSI/ASSP Z9.14-2020 Testing and Performance-Verification Methodologies for Biosafety Level 3 (BSL-3) and Animal Biosafety Level 3 (ABSL-3) Ventilation Systems.ANSI/ASSP Z9.14-2020生物安全三级(BSL-3)和动物生物安全三级(ABSL-3)通风系统的测试与性能验证方法
Appl Biosaf. 2020 Dec 1;25(4):181-183. doi: 10.1177/1535676020925562.
4
Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.实验室生物安全措施涉及 SARS-CoV-2 和被归类为 3 级风险的生物制剂。
Pathology. 2020 Dec;52(7):790-795. doi: 10.1016/j.pathol.2020.09.006. Epub 2020 Sep 30.
5
Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to COVID.决定 COVID-19 传播的因素及预防未来类似 COVID 加速病毒传染性的建议策略
Sci Total Environ. 2020 Aug 10;729:138474. doi: 10.1016/j.scitotenv.2020.138474. Epub 2020 Apr 20.
6
Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review.冠状病毒病(COVID-19)的现状和未来展望:叙事性综述。
Int J Environ Res Public Health. 2020 Apr 14;17(8):2690. doi: 10.3390/ijerph17082690.
7
Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea.韩国 2019 冠状病毒病(COVID-19)实验室诊断指南。
Ann Lab Med. 2020 Sep;40(5):351-360. doi: 10.3343/alm.2020.40.5.351.
8
Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel.人类和动物医学诊断实验室安全工作规范。疾病控制与预防中心召集的生物安全蓝带小组的建议。
MMWR Suppl. 2012 Jan 6;61(1):1-102.

生物安全3级核心设施中应对新出现病原体生物安全和生物安保的管理体系方法

Management System Approach for Addressing Biosafety and Biosecurity of Emerging Pathogens in a Biosafety Level-3 Core Facility.

作者信息

Joseph Tessy

机构信息

BSL-3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

出版信息

Appl Biosaf. 2021 Dec 1;26(4):210-220. doi: 10.1089/apb.2021.0007. Epub 2021 Nov 24.

DOI:10.1089/apb.2021.0007
PMID:36034099
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9134332/
Abstract

The biosafety level-3 (BSL-3) core facility (CF) at Yong Loo Lin School of Medicine (NUS Medicine) in National University of Singapore (NUS) has adopted international standards and guidelines to establish a biorisk management (BRM) system that helps to improve its BRM system and consistently minimize the risks to employees, the public, and the environment to an acceptable level while working with SARS-CoV-2. When the NUS Medicine BSL-3 CF started its operations, the Occupational Health and Safety Assessment Series 18001:2007 and the CEN Workshop Agreement 15793:2011 guidelines were used to establish its first BRM framework. The BRM framework provided the roadmap of how to organize, systematically manage, and structure the various biorisk programs that was then modified according to International Organization for Standardization 35001:2019 during the coronavirus disease 2019 pandemic in 2020 to address the specific circumstances. Adopting a management system approach allowed BSL-3 CF to efficiently manage its BRM even during unpredicted emerging pandemic situations. It resulted in integrating a risk management process into daily laboratory operations and ongoing identification of hazards, prioritization of risks, and the establishment of risk mitigation measures specific to SARS-CoV-2. In addition, the implementation of a BRM system in the BSL-3 CF has increased biorisk awareness among BSL-3 CF users and encouraged every stakeholder to take ownership of their activities, and continual improvements in mitigation of biorisks. This article summarizes the systematic approaches and major elements of the BRM systems adopted by NUS Medicine BSL-3 CF for the implementation of biosafety and biosecurity precautions, and control measures to minimize the risk of research activities using various RG3 biological agents including SARS-CoV-2.

摘要

新加坡国立大学杨秀桃医学院的生物安全三级(BSL-3)核心设施(CF)采用了国际标准和指南,建立了生物风险管理(BRM)系统,以改进其BRM系统,并在处理严重急性呼吸综合征冠状病毒2(SARS-CoV-2)时,持续将对员工、公众和环境的风险降至可接受水平。当新加坡国立大学杨秀桃医学院BSL-3核心设施开始运营时,使用了职业健康与安全评估系列标准18001:2007和欧洲标准化委员会研讨会协议15793:2011指南来建立其首个BRM框架。该BRM框架提供了如何组织、系统管理和构建各种生物风险计划的路线图,然后在2020年冠状病毒病大流行期间,根据国际标准化组织35001:2019进行了修改,以应对具体情况。采用管理系统方法使BSL-3核心设施即使在不可预测的新出现的大流行情况下也能有效管理其BRM。这导致将风险管理过程整合到日常实验室操作中,并持续识别危害、确定风险优先级以及制定针对SARS-CoV-2的风险缓解措施。此外,在BSL-3核心设施中实施BRM系统提高了BSL-3核心设施用户的生物风险意识,并鼓励每个利益相关者对其活动负责,以及在生物风险缓解方面不断改进。本文总结了新加坡国立大学杨秀桃医学院BSL-3核心设施采用的BRM系统的系统方法和主要要素,以实施生物安全和生物安保预防措施,以及控制措施,以尽量降低使用包括SARS-CoV-2在内的各种风险组3生物制剂进行研究活动的风险。